GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2020-05-21

Last Posted Date: 2023-10-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT04398680

Locations: 🇰🇷
GSK Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of

A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin

First Posted Date: 2020-05-21

Last Posted Date: 2025-05-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT04398745

Locations: 🇸🇬
GSK Investigational Site, Singapore, Singapore

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

Phase 2

Completed

Conditions: Severe Acute Respiratory Syndrome

Interventions: Biological: Placebo 1
Biological: Otilimab
Biological: Placebo 2
Drug: Standard of care

First Posted Date: 2020-05-06

Last Posted Date: 2022-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1156

Registration Number: NCT04376684

Locations: 🇬🇧
GSK Investigational Site, Liverpool, United Kingdom

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers
Asthma

Interventions: Biological: melrilimab (GSK3772847) 70 milligram (mg)
Other: Placebo
Biological: melrilimab (GSK3772847) 140 milligram (mg)

First Posted Date: 2020-04-28

Last Posted Date: 2021-11-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 65

Registration Number: NCT04366349

Locations: 🇺🇸
GSK Investigational Site, Anaheim, California, United States

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: Bintrafusp alfa

First Posted Date: 2020-04-16

Last Posted Date: 2024-04-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 25

Registration Number: NCT04349280

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Phase 3

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Biological: Otilimab (GSK3196165)
Drug: csDMARD(s)

First Posted Date: 2020-04-03

Last Posted Date: 2024-02-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2916

Registration Number: NCT04333147

Locations: 🇬🇧
GSK Investigational Site, Coventry, United Kingdom

Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Antifungal Agents

Interventions: Drug: Griseofulvin 500 mg
Drug: Griseofulvin 250 mg
Drug: Reference Griseofulvin 500 mg

First Posted Date: 2020-03-24

Last Posted Date: 2020-12-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT04318535

Locations: 🇮🇳
GSK Investigational Site, Navi Mumbai, India

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Combination Product: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)
Biological: Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
Combination Product: Placebo